NovoCure Limited (NVCR) Operating cash flow 2017–2026
NovoCure Limited (NVCR) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$49.0MFY2026 · since FY2017: -$107.6M → -$49.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$49.0M | -85.9% |
| FY2025 | -$26.4M | +64.0% |
| FY2024 | -$73.3M | -338.2% |
| FY2023 | $30.8M | -62.8% |
| FY2022 | $82.8M | -16.5% |
| FY2021 | $99.1M | +272.5% |
| FY2020 | $26.6M | +1527.3% |
| FY2019 | -$1.9M | +94.4% |
| FY2018 | -$33.1M | +69.2% |
| FY2017 | -$107.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NVCR financial trends
NVCR RevenueNVCR Net incomeNVCR Net marginNVCR Gross profitNVCR Gross marginNVCR Operating incomeNVCR Operating marginNVCR Free cash flowNVCR Capital expendituresNVCR Return on equityNVCR Stock buybacksNVCR Dividends paidNVCR Total assetsNVCR Total liabilitiesNVCR Shareholders’ equityNVCR overview →